New diabetes pill PS1 enters first human safety tests

NCT ID NCT05176210

Completed Disease control Sponsor: Pharmasaga Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests PS1, a new tablet designed to help control blood sugar in people with type 2 diabetes. It is the first time PS1 is given to humans, so the main goal is to check its safety and how the body handles it. The trial includes healthy volunteers and people with type 2 diabetes, and some participants will receive a placebo. Results will help determine if PS1 is safe enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PS1 (oral tablet)
What this could lead to: If safe and effective, PS1 could become a new option to help control blood sugar in people with type 2 diabetes.
What could go wrong: This is a very early, first-in-human study focused on safety, not proof of effectiveness. The drug may cause side effects or fail to work in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE II DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE II DIABETES

Contacts and locations

Show contact details

Locations

Mingche Liu

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.